Fudion

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fudion

Property Description
Active Ingredient Fusidic Acid (or Sodium Fusidate)
Forms Cream, Ointment, Eye Drops, Oral Tablets, Injectable Solution
Pharmacological Class Antibiotic (Steroid Antibacterial)
Common Purpose To halt the growth of susceptible bacterial infections
Origin Semisynthetic (derived from the fungus Fusidium coccineum)

What Type of Medicine Is Fudion?

Fudion is a recognized brand name preparation that contains the active substance Fusidic Acid (INN), and is strictly categorized as a prescription-only antibiotic or antibacterial agent. Its classification is notable because the active substance, Fusidic Acid, is a semisynthetic compound, originally derived from the fungus Fusidium coccineum.

The unusual structure of Fusidic Acid places it within the fusidane class of antibiotics. This unique structure is clinically recognized for effective targeting of Gram-positive organisms, particularly against Staphylococcus aureus, which differentiates it from general-purpose, broad-spectrum antibiotics.

Fudion's Unique Composition and Forms

The formulation of Fudion is based on the single active ingredient, Fusidic Acid (often as its sodium salt), and is consistently supplied as a monotherapy product. The drug is characterized by rapid action against susceptible bacteria.

Fudion is distinguished by its extensive range of dosage forms, allowing for highly tailored treatment. This includes the most common topical preparations (such as creams and ointments), specific eye drop formulations, and, for deep or systemic infections, oral tablets or injectable solutions. This versatility ensures the active ingredient can be delivered appropriately for the site of infection.

General Role of Fusidic Acid in Treatment

The primary therapeutic purpose of Fusidic Acid is the effective management of bacterial infections by exerting a powerful bacteriostatic effect against the invading microbes. Its action is highly selective; it inhibits the growth and spread of bacteria by interfering with their ability to synthesize the essential proteins required for their survival.

By selectively halting the bacterial growth process, Fudion prevents the infection from advancing, which is its general clinical role. The preparation is thus used to control the infection, ensuring that the microbial load is suppressed while the body’s natural defenses can clear the issue.

What side effects are possible with Fudion?

Possible Side Effects and Safety Information

The safety profile for Fudion (Fusidic Acid) is formally categorized based on the route of administration, with documentation provided by government regulatory agencies. Adverse reactions are grouped by the body system affected and their reported frequency.

For topical forms (creams and ointments), the most frequently reported adverse reactions are Common local effects, including pruritus (itching), rash, erythema, and irritation at the application site. For systemic forms (oral or injectable), Common effects include gastrointestinal disturbances such as vomiting and diarrhoea.

Systemic Safety and Serious Reactions

The official classification of adverse reactions involves several System-Organ Classes, including Skin and Subcutaneous Tissue Disorders, Gastrointestinal Disorders, and Hepatobiliary Disorders. Reactions affecting the liver, such as transient elevation in liver enzymes and jaundice, are considered Uncommon but are noted with systemic use. Rare but clinically significant adverse effects include Angioedema and severe, life-threatening events such as Anaphylactic Shock and Serious Cutaneous Adverse Reactions (SCARs), though their frequency is sometimes classified as Not Known (post-marketing reports).

Population-Specific Safety Constraints

The regulatory label includes specific safety constraints, noting that systemic use is typically contraindicated in patients with a history of severe hepatic impairment. Caution is also advised when administering systemic Fusidic Acid to neonates due to the theoretical risk of kernicterus. Furthermore, regulatory documents specify that serious cutaneous reactions usually appear in the first weeks of therapy and that extended or recurrent use may increase the risk of contact sensitization.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Fudion

The following information summarizes the official regulatory guidance concerning overdose for the product Fudion (enfuvirtide).

According to authoritative government regulatory documents, the official overdose profile is characterized by a lack of reported adverse events even at doses significantly higher than typical therapeutic exposure.

Documented Exposure and Clinical Observations

Exposure Context Official Observation
High-Dose Clinical Trial Exposure Doses up to 200 mg administered twice daily for 14 days did not result in an increased frequency of adverse reactions in adult patients.
Highest Recorded Single Overdose A single dose of 2,400 mg was recorded, and the patient experienced no adverse events following the exposure.

Emergency Actions and Required Care

  • Required Medical Action: The official regulatory documentation explicitly states that treatment of an overdose should be supportive.
  • When to Seek Help: Although no specific acute adverse events have been documented for the highest recorded overdose, immediate contact with a healthcare professional or Poison Help is necessary in any suspected overdose situation to ensure appropriate supportive care is provided.

Regulatory Summary

The established regulatory profile dictates that there are no specific, known toxic clinical manifestations or symptoms linked to an overdose based on clinical experience to date. The instruction for supportive treatment is the primary procedural guidance for healthcare providers in an overdose context.

Therapeutic Uses of Fudion

Fudion (Fusidic Acid) is commonly used to help manage conditions presenting with systemic or localized discomfort. Its primary use is to address bacterial skin and eye infections, relevant in contexts marked by increased discomfort, including conditions where symptoms relate to inflammatory or irritative states.

This medication is relevant for easing symptom clusters that may become intense in acute, localized infections, such as impetigo, folliculitis, and furuncles (boils). It is also applied in settings that involve acute or unstable symptom patterns, including the management of infected wounds, secondary infections of eczema, and bacterial conjunctivitis.

“Fudion is applied across therapeutic domains where additional symptomatic support is needed to address acute, localized bacterial episodes and their associated discomfort.”

In more serious scenarios, Fudion may be part of symptomatic management for deep-seated staphylococcal infections affecting the bone or joints, providing support that contributes to improved comfort during difficult episodes.


Quick Fact: Relief for Symptoms related to Inflammatory or Irritative States and Ocular Irritation


Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Fudion

The eligibility for Fudion (Fusidic Acid) is strictly governed by governmental regulatory standards, differentiating restrictions primarily based on the route of administration (systemic versus topical).

Absolute Contraindications (Must Not Use)

  • Hypersensitivity: Fudion is contraindicated in patients with a known allergy to Fusidic Acid, Sodium Fusidate, or any of the product’s excipients (All forms).
  • Concomitant Statins: Systemic Fudion is strictly contraindicated if a patient is also receiving statin medication (HMG-CoA reductase inhibitors).
  • Metabolic Disorders: Specific oral forms are contraindicated in patients with rare hereditary issues like galactose intolerance due to excipient content.

Conditional Use and Age Restrictions

  • Organ Function: Systemic use requires caution and monitoring in patients with impaired hepatic function or biliary tract obstruction.
  • Pregnancy and Lactation: Topical/ophthalmic Fudion is generally permitted. However, systemic use is preferable to avoid during pregnancy and breastfeeding.
  • Pediatrics: Topical forms are allowed for all ages. Systemic use in neonates requires particular care due to the theoretical risk concerning bilirubin metabolism.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for systemic Fudion (Fusidic Acid), which applies to oral and injectable formulations. The topical forms (cream, ointment, eye drops) are associated with negligible systemic absorption and minimal interaction risk.

Contraindicated Combinations and Timing Rules

Co-administration of systemic Fudion with Statins (HMG-CoA Reductase Inhibitors) is formally contraindicated in regulatory documents due to the official risk of rhabdomyolysis. Statin therapy must be discontinued during Fudion treatment and may only be safely reintroduced seven days after the last dose of systemic Fudion.

Exposure-Altering Interactions

Other drugs classified as having clinically significant interactions may alter plasma concentrations and increase toxicity risk. The concomitant use of Fudion with HIV Protease Inhibitors (e.g., Ritonavir, Saquinavir) is not recommended because it can cause increased plasma concentrations of both agents, which carries a risk of hepatotoxicity. Fudion may also alter the anticoagulant effect of Oral Anticoagulants (Coumarin derivatives, such as Warfarin), requiring careful monitoring of the anticoagulant status.

Population-Specific Cautions

Fudion's competitive inhibition of bilirubin binding to albumin requires particular caution in neonates due to the theoretical risk of kernicterus. Caution is also advised in patients with hepatic dysfunction or biliary disease, as Fudion is metabolized in the liver.

Mechanism of Action

Molecular Lock on Bacterial Protein Synthesis

Fudion (Fusidic Acid) initiates its effect by acting as a specific non-competitive inhibitor of the essential bacterial enzyme Elongation Factor G (EF-G). The drug binds to and stabilizes the EF-G-ribosome complex, preventing the enzyme from detaching and recycling, which physically arrests the elongation phase of protein synthesis. This blockade of the machinery responsible for manufacturing new proteins leads to the fundamental physiological consequence of halting bacterial growth.


Causal Chain: Arrested Growth to Microbial Suppression

The molecular 'locking' of EF-G results in the cessation of all new polypeptide chain growth, which prevents the susceptible bacterial population from replicating and spreading. This physiological consequence is known as a bacteriostatic effect, where the microbial population is suppressed. The mechanism of action functionally arrests proliferation, which limits the microbial load and makes the stationary, non-proliferating bacteria available for clearance by host immune cells.


Inherent Mechanism Constraints

The drug's mechanism is intrinsically constrained by bacterial physiology, rendering it ineffective against most Gram-negative bacteria because they possess an outer membrane that prevents the drug from reaching its internal ribosomal target. Furthermore, the action can be overcome by acquired resistance mechanisms, such as FusB-type proteins, which actively interfere with the drug's binding site to release EF-G, allowing protein synthesis to resume and circumventing the inhibitory effect.

Dosage and Administration Information

How Fudion is Used

The use of Fudion (Fusidic Acid/Sodium Fusidate) is defined by the severity and location of the infection, which determines the specific route of administration and dosage form. The medication is officially available for use via four primary routes: Topical (cream or ointment), Ophthalmic (viscous eye drops), Oral (tablets or suspension), and Intravenous (IV) Infusion.

Administration and Standard Dosing

The required dose and frequency are based on the intended treatment delivery.

Administration Route Typical Adult Dosing Frequency Pattern
Oral/IV Systemic 500 mg of sodium fusidate Three times daily (TID)
Topical (Cream/Ointment) A thin layer applied gently Three or four times daily
Ophthalmic (Drops/Gel) One drop to the affected eye(s) Twice daily (BID)

For Intravenous Infusion, the 500 mg powder must be reconstituted and diluted in 500 mL of infusion fluid. This preparation is then administered over a controlled period, ranging from 2 to 6 hours depending on the type of venous line used.

Usage Duration and Adjustments

Fudion treatment duration varies, typically lasting 1 to 2 weeks for localized topical infections. Ophthalmic use requires continuation for at least 48 hours after the eye appears clinically normal. For systemic infections, prolonged courses may be necessary. Dosing rules for specific populations mandate that no dosage adjustment is required for patients with renal impairment, as the drug is primarily eliminated via the bile. Pediatric systemic dosing is based on a weight-based calculation. A key procedural restriction for ophthalmic use is the requirement to remove contact lenses before application.

Recent Clinical Evidence

Overview of Research Evidence for Fudion (Fusidic Acid)

The available research evidence for Fudion (Fusidic Acid) consists primarily of controlled clinical trials, systematic reviews, and observational studies. This research has examined how the medicine was evaluated when used for specific bacterial infections. It is important to remember that study results describe group patterns and do not determine whether an individual will respond similarly.


Evidence for Topical Use in Localized Bacterial Skin Infections

The research exploring Fusidic Acid cream and ointment was largely conducted on patients with conditions such as impetigo, folliculitis, and secondarily infected eczema. These studies include numerous short-term Randomized Controlled Trials (RCTs), where Fusidic Acid was evaluated against either a non-active placebo or other topical antibiotic options.

Researchers focused on measuring overall clinical status of the lesions, meaning how well the sores or blisters changed. They also monitored the microbiological eradication of the target bacteria, primarily Staphylococcus aureus. Findings describe patterns observed in the studies related to the change in skin irritation and discomfort over the treatment period, typically lasting 7 to 14 days. What remains uncertain relates to the availability of more comprehensive data on long-term outcomes. Follow-up durations were limited.


Evidence for Systemic Use in Deep-Seated Staphylococcal Infections

For severe or deep-seated issues, such as bacterial infections affecting bone or joints, the research studies the oral or injectable forms of Fusidic Acid. Because of the seriousness of these infections, Fusidic Acid was usually evaluated as a component of a multi-drug combination regimen rather than alone. Evidence for this use is often derived from smaller clinical studies and observational settings.

Studies monitored key outcomes related to physiological strain and long-term functional status. Reports documented the measured rate of microbiological disappearance from tissues and joints following extended courses of combination therapy. Findings were mixed across studies due to the fact that patient groups in this area are complex and diverse. Data for certain subgroups, such as those with specific comorbidities, remain insufficient.


Research Gaps and Areas of Scientific Uncertainty

The research landscape highlights several areas where more information is needed. Comparative evidence is lacking in some contexts, meaning more head-to-head trials against all available antibiotic options would contribute to the broader evidence landscape. The evidence quality varies across studies, particularly for the more severe, systemic infections where sample sizes were often modest. There is also a continuous need for research to monitor and manage the emergence of antibiotic resistance, as this factor may change future treatment approaches.

Key Studies & References

  1. FUCITHALMIC 1% Viscous Eye Drops (fusidic acid) - Health Canada Product Monograph (Pediatric/Geriatric data reference)

Frequently Asked Questions (FAQ)

Common questions about Fudion (FAQ)


Q: How quickly should I expect to feel better after starting Fudion?

A: Studies and official information indicate that the time to feel better can depend on the infection being treated. For localized topical infections, clinical improvement is often assessed within 7 to 14 days of starting treatment. For the eye drop formulation, it is intended to be continued for a specific period after clinical improvement is noted, such as 48 hours.


Q: Is Fudion known to cause stomach upset or nausea?

A: Official product information states that gastrointestinal issues are common with the systemic forms (oral or IV) of Fudion. These common effects can include vomiting and diarrhoea. Nausea and abdominal pain have also been reported in clinical data.


Q: Can elderly patients safely take Fudion?

A: Regulatory guidance indicates that no specific dose adjustment is typically needed for patients with normal kidney function, including the elderly. However, Fudion is processed by the liver, so caution and monitoring are advised for any patient with pre-existing liver issues.


Q: Are there any specific foods or drinks to avoid while on Fudion?

A: Official regulatory documents list several important drug-drug interactions, but they typically do not specify general food or drink restrictions. Patients should consult the patient information leaflet or their healthcare provider regarding any dietary concerns.


Q: How long does Fudion stay in your system after stopping it?

A: The clearance of Fudion from the body is relatively slow. The official guidance regarding its interaction with statins requires statins to be withheld for seven days after the last dose of systemic Fudion, which indicates the drug is present in the system for at least this period.


Q: Does Fudion affect sleep patterns?

A: Sleep-related issues such as somnolence (drowsiness) or insomnia (difficulty sleeping) are not usually listed as common or uncommon side effects in the main regulatory documents.


Q: Is it normal to feel a bit tired when first starting Fudion?

A: Fatigue or lethargy (feeling generally tired) has been reported in clinical data as a less common adverse reaction associated with the systemic use of Fudion.


Q: Can Fudion be crushed, cut, or chewed?

A: Regulatory guidance advises against altering the tablets (crushing, cutting, or chewing) unless specifically advised by a healthcare professional. Alternative formulations, such as an oral suspension, are typically available for those who have difficulty swallowing.


Q: Are there different brand names for the medicine Fudion?

A: Yes, Fudion is a recognized brand name for the active ingredient, Fusidic Acid (or Sodium Fusidate). The active ingredient is also sold under other common brand names and generic versions across different regions globally.


Q: What kind of monitoring is needed while taking Fudion?

A: For systemic use, official warnings specify the need for monitoring liver function, especially if there is pre-existing hepatic impairment. If Fudion is taken alongside specific blood thinners (like Warfarin), monitoring of anticoagulant status is also required due to potential interaction.


Q: Does Fudion affect liver enzyme levels?

A: Yes, official safety information indicates that Fudion can affect the liver. Transient elevation in liver enzymes (markers like ALT and AST) and jaundice (yellowing of the skin or eyes) have been reported as uncommon adverse reactions with systemic use.


Q: Can Fudion be used by people who have a history of heart problems?

A: The most significant precaution related to heart conditions is the strict contraindication against using systemic Fudion while taking statin medications, which are common for cholesterol management. Beyond this specific drug interaction, other general cardiac conditions are not universally contraindicated.


Q: Is it common to experience headaches after starting Fudion?

A: Headaches are listed in clinical data as a reported adverse reaction for systemic Fudion. It is typically classified as a common or less common effect in the product information.


Q: What happens if I accidentally take more Fudion than prescribed?

A: Official regulatory guidance states that accidental overdose is generally unlikely to cause serious harm, particularly with topical forms. However, if a large quantity of the systemic form is ingested or if a serious reaction occurs, official guidance advises that immediate medical attention should be sought.


Q: Are there any common interactions between Fudion and herbal remedies?

A: Regulatory sources generally state that there are no known issues with taking common herbal remedies, vitamins, or nutritional supplements at the same time as Fudion. It is always recommended that patients inform their healthcare professional of all products being used to avoid potential interactions.


Q: Is it possible for Fudion to cause a rash?

A: Yes, rash is a recognized potential side effect of Fudion. For topical use, local effects like rash and irritation at the application site are common. For systemic use, rare but serious cutaneous adverse reactions (SCARs) are also noted in the product safety profile.


Q: Are there specific symptoms that warrant calling a doctor immediately while on Fudion?

A: Yes, official patient information advises seeking immediate medical attention for symptoms indicating a severe allergic reaction (such as difficulty breathing, or swelling of the face, lips, or tongue). Signs of potential liver problems, like jaundice (yellowing of the skin/eyes), also warrant immediate consultation.


Q: What are the signs that Fudion might not be working for me?

A: Official patient information often recommends consulting with a healthcare professional if the symptoms of the infection do not begin to improve within a few days of starting Fudion, or if the symptoms worsen.


Q: Will taking Fudion impact my ability to drive or operate machinery?

A: Regulatory information states that topical forms are not expected to affect the ability to drive or use machines. However, systemic forms may cause side effects like dizziness which could impair concentration or reaction time. If you experience such effects, official advice recommends caution.


Q: Does Fudion have to be taken with food, or can I take it on an empty stomach?

A: Oral Fudion is readily absorbed, but its absorption can be variable. Specific administration instructions, such as whether to take the dose with food or on an empty stomach, are typically detailed in the dispensing information and should be followed.


Q: Is Fudion available as a generic medicine?

A: Yes, the active ingredient in Fudion, Fusidic Acid (or Sodium Fusidate), is available from various manufacturers under generic names and other established brand names around the world.

How should Fudion be stored and disposed of?

How to Store and Dispose of Fudion (Fusidic Acid)

Official regulatory guidelines dictate specific conditions for storing and discarding Fudion preparations to ensure product integrity and safety.

Storage Requirements

Fudion must be stored at controlled room temperature, typically at or below 25 C or 30 C depending on the formulation. It is strictly required to keep the medicine out of the sight and reach of children.

  • Do not refrigerate or freeze the medicine.
  • Store the product in its original container, protected from direct light and moisture, with the container tightly closed.

Stability and Disposal

For creams, ointments, and eye drops, any unused product must be discarded 28 days after the first opening. Unused or expired Fudion must not be disposed of in household wastewater (sinks or toilets). The preferred method for discarding the medicine is returning it to a local collection point or pharmacy through an official drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fudion found in:

A-Z Index: